Euris et Inria proposent une solution de gestion et de partage sécurisés des données d’imagerie médicale
December 04, 2024 08:30 ET
|
Euris Health Cloud
Communiqué de presse Euris et Inria proposent une solution de gestion et de partage sécurisés des données...
TechFlow Secures 7-Year $2.1 Billion TSA Contract for Explosives Detection System Upkeep at Over 300 Facilities Spanning the U.S. and its Territories
December 07, 2023 08:00 ET
|
TechFlow, Inc.
TechFlow Secures 7-Year $2.1 Billion TSA Contract for Explosives Detection System Upkeep at Over 300 Facilities Spanning the U.S. and its Territories
Axsome Therapeutics Announces Sunosi® (Solriamfetol) Meets Primary Endpoint Demonstrating Improvement in Cognitive Function in the SHARP Trial in Cognitively Impaired Patients with Excessive Daytime Sleepiness Associated with Obstructive Sleep Apnea
October 03, 2022 06:30 ET
|
Axsome Therapeutics, Inc.
Statistically significant improvement in cognitive function, as measured by the DSST RBANS compared to placebo (p=0.009, primary endpoint) Statistically significant patient-reported improvement in...
Axsome Therapeutics Announces Publication of Post-hoc Analysis of Sunosi® Effect on Excessive Daytime Sleepiness in Narcolepsy or Obstructive Sleep Apnea Patients with a History of Depression in the Journal of Psychiatric Research
September 07, 2022 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
Axsome Therapeutics Hosts Sunosi® Investor Update Virtual Event Today with Key Opinion Leaders
June 28, 2022 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, June 28, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
Axsome Therapeutics to Host Sunosi® Investor Update Virtual Event
June 22, 2022 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, June 22, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
Axsome Therapeutics to Acquire Sunosi® from Jazz Pharmaceuticals, Expanding Axsome’s Leadership in Neuroscience
March 28, 2022 06:00 ET
|
Axsome Therapeutics, Inc.
Sunosi is the first and only dual-acting dopamine and norepinephrine reuptake inhibitor (DNRI) approved by the FDA to improve wakefulness in adults living with excessive daytime sleepiness associated...
AVX to Attend & Announce New Products at EDS 2015
April 28, 2015 13:22 ET
|
AVX Corporation
GREENVILLE, S.C., April 28, 2015 (GLOBE NEWSWIRE) -- AVX Corporation, a leading manufacturer of passive components and interconnect solutions, is attending the 2015 Electronic Distribution Show (EDS),...
AVX & AVNET CELEBRATE 50 YEARS OF SUCCESS
August 05, 2013 16:51 ET
|
AVX Corporation
GREENVILLE, S.C., Aug. 5, 2013 (GLOBE NEWSWIRE) -- AVX Corporation, a leading manufacturer of passive components and interconnect solutions, has become the first passive supplier to celebrate a...